The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 17, 2026 | Fouse Jacqualyn A | Director | Grant(A) | 454 | — | $0 |
| Jun 17, 2026 | Fouse Jacqualyn A | Director | Grant(A) | 766 | — | $0 |
| Jun 17, 2026 | Daly James M | Director | Grant(A) | 454 | — | $0 |
| Jun 17, 2026 | Daly James M | Director | Grant(A) | 766 | — | $0 |
| Jun 17, 2026 | Baker Bros. Advisors LP | Director | Grant(A) | 908 | — | $0 |
| Jun 17, 2026 | Baker Bros. Advisors LP | Director | Grant(A) | 908 | — | $0 |
| Jun 17, 2026 | Baker Bros. Advisors LP | Director | Grant(A) | 2K | — | $0 |
| Jun 17, 2026 | Baker Bros. Advisors LP | Director | Grant(A) | 2K | — | $0 |
| Jun 17, 2026 | Brennan Daniel J. | Director | Grant(A) | 404 | — | $0 |
| Jun 17, 2026 | Brennan Daniel J. | Director | Grant(A) | 681 | — | $0 |
| Jun 17, 2026 | Taub Rebecca | Director | Grant(A) | 454 | — | $0 |
| Jun 17, 2026 | Taub Rebecca | Director | Grant(A) | 766 | — | $0 |
| Jun 17, 2026 | Levy Richard S | Director | Grant(A) | 454 | — | $0 |
| Jun 17, 2026 | Levy Richard S | Director | Grant(A) | 766 | — | $0 |
| Jun 1, 2026 | Soergel David | Chief Medical Officer | Sell(S) | 1K | $495.74 | $517K |
| May 22, 2026 | Levy Richard S | Director | Sell(S) | 40 | $506.68 | $20K |
| May 22, 2026 | Levy Richard S | Director | Sell(S) | 320 | $508.24 | $163K |
| May 22, 2026 | Levy Richard S | Director | Sell(S) | 151 | $510.36 | $77K |
| May 22, 2026 | Levy Richard S | Director | Sell(S) | 610 | $511.40 | $312K |
| May 22, 2026 | Levy Richard S | Director | Sell(S) | 439 | $512.50 | $225K |
| May 22, 2026 | Levy Richard S | Director | Sell(S) | 40 | $512.97 | $21K |
| May 22, 2026 | Levy Richard S | Director | Sell(S) | 343 | $514.67 | $177K |
| May 22, 2026 | Levy Richard S | Director | Sell(S) | 657 | $515.92 | $339K |
| May 22, 2026 | Levy Richard S | Director | Sell(S) | 723 | $516.87 | $374K |
| May 22, 2026 | Levy Richard S | Director | Sell(S) | 1K | $517.59 | $775K |
| May 22, 2026 | Levy Richard S | Director | Sell(S) | 782 | $518.76 | $406K |
| May 22, 2026 | Levy Richard S | Director | Sell(S) | 80 | $519.98 | $42K |
| May 18, 2026 | Soergel David | Chief Medical Officer | Sell(S) | 844 | $515.90 | $435K |
| Mar 6, 2026 | Taub Rebecca | Director | Sell(S) | 491 | $431.94 | $212K |
| Mar 6, 2026 | Huntsman Carole | Chief Commercial Officer | Sell(S) | 419 | $431.94 | $181K |
| Mar 6, 2026 | Kelley Shannon T | General Counsel | Sell(S) | 360 | $431.94 | $155K |
| Mar 6, 2026 | Sibold William John | President and CEO, Director | Sell(S) | 2K | $431.94 | $718K |
| Mar 6, 2026 | Dier Mardi | EVP and CFO | Sell(S) | 160 | $434.20 | $69K |
| Mar 6, 2026 | Dier Mardi | EVP and CFO | Sell(S) | 80 | $435.32 | $35K |
| Mar 6, 2026 | Dier Mardi | EVP and CFO | Sell(S) | 80 | $436.69 | $35K |
| Mar 6, 2026 | Dier Mardi | EVP and CFO | Sell(S) | 40 | $437.65 | $18K |
| Mar 6, 2026 | Dier Mardi | EVP and CFO | Sell(S) | 646 | $431.94 | $279K |
| Mar 6, 2026 | Dier Mardi | EVP and CFO | Sell(S) | 40 | $425.08 | $17K |
| Mar 6, 2026 | Dier Mardi | EVP and CFO | Sell(S) | 420 | $426.86 | $179K |
| Mar 6, 2026 | Dier Mardi | EVP and CFO | Sell(S) | 80 | $427.85 | $34K |
| Mar 6, 2026 | Dier Mardi | EVP and CFO | Sell(S) | 160 | $429.00 | $69K |
| Mar 6, 2026 | Dier Mardi | EVP and CFO | Sell(S) | 40 | $429.58 | $17K |
| Mar 6, 2026 | Dier Mardi | EVP and CFO | Sell(S) | 120 | $430.90 | $52K |
| Mar 6, 2026 | Dier Mardi | EVP and CFO | Sell(S) | 116 | $432.56 | $50K |
| Mar 4, 2026 | Soergel David | Chief Medical Officer | Grant(A) | 4K | — | $0 |
| Mar 4, 2026 | Soergel David | Chief Medical Officer | Grant(A) | 5K | — | $0 |
| Mar 4, 2026 | Huntsman Carole | Chief Commercial Officer | Grant(A) | 4K | — | $0 |
| Mar 4, 2026 | Huntsman Carole | Chief Commercial Officer | Grant(A) | 5K | — | $0 |
| Mar 4, 2026 | Kelley Shannon T | General Counsel | Grant(A) | 4K | — | $0 |
| Mar 4, 2026 | Kelley Shannon T | General Counsel | Grant(A) | 5K | — | $0 |
| Mar 4, 2026 | Sibold William John | President and CEO, Director | Grant(A) | 15K | — | $0 |
| Mar 4, 2026 | Sibold William John | President and CEO, Director | Grant(A) | 19K | — | $0 |
| Mar 4, 2026 | Dier Mardi | EVP and CFO | Grant(A) | 5K | — | $0 |
| Mar 4, 2026 | Dier Mardi | EVP and CFO | Grant(A) | 7K | — | $0 |
| Mar 2, 2026 | Dier Mardi | EVP and CFO | Sell(S) | 1K | $427.21 | $505K |
| Feb 23, 2026 | Levy Richard S | Director | Option exercise(M) | 3K | $7.36 | $18K |
| Feb 23, 2026 | Levy Richard S | Director | Option exercise(M) | 3K | — | $0 |
| Jan 26, 2026 | Taub Rebecca | Director | Sell(S) | 647 | $492.42 | $319K |
| Jan 26, 2026 | Sibold William John | President and CEO, Director | Sell(S) | 2K | $492.42 | $777K |
| Jan 26, 2026 | Huntsman Carole | Chief Commercial Officer | Sell(S) | 570 | $494.59 | $282K |
| Jan 26, 2026 | Huntsman Carole | Chief Commercial Officer | Sell(S) | 340 | $492.42 | $167K |
| Jan 26, 2026 | Levy Richard S | Director | Option exercise(M) | 4K | $16.46 | $66K |
| Jan 26, 2026 | Levy Richard S | Director | Option exercise(M) | 4K | — | $0 |
| Jan 20, 2026 | Taub Rebecca | Director | Sell(S) | 2K | $490.77 | $1.1M |
| Jan 20, 2026 | Kelley Shannon T | General Counsel | Sell(S) | 429 | $501.40 | $215K |
| Jan 20, 2026 | Kelley Shannon T | General Counsel | Sell(S) | 263 | $490.77 | $129K |
| Jan 15, 2026 | Thakkar Rita | Chief Accounting Officer | Grant(A) | 2K | — | $0 |
| Jan 15, 2026 | Thakkar Rita | Chief Accounting Officer | Grant(A) | 2K | — | $0 |
| Jan 9, 2026 | Taub Rebecca | Director | Sell(S) | 465 | $528.16 | $246K |
| Jan 9, 2026 | Taub Rebecca | Director | Sell(S) | 554 | $529.28 | $293K |
| Jan 9, 2026 | Taub Rebecca | Director | Sell(S) | 256 | $530.45 | $136K |
| Jan 9, 2026 | Taub Rebecca | Director | Sell(S) | 30 | $531.05 | $16K |
| Jan 9, 2026 | Taub Rebecca | Director | Sell(S) | 40 | $532.50 | $21K |
| Jan 9, 2026 | Taub Rebecca | Director | Sell(S) | 271 | $534.18 | $145K |
| Jan 9, 2026 | Taub Rebecca | Director | Sell(S) | 89 | $534.93 | $48K |
| Jan 9, 2026 | Taub Rebecca | Director | Sell(S) | 299 | $535.80 | $160K |
| Jan 9, 2026 | Taub Rebecca | Director | Sell(S) | 385 | $536.88 | $207K |
| Jan 9, 2026 | Taub Rebecca | Director | Sell(S) | 40 | $537.84 | $22K |
| Jan 9, 2026 | Taub Rebecca | Director | Sell(S) | 400 | $539.26 | $216K |
| Jan 9, 2026 | Taub Rebecca | Director | Sell(S) | 40 | $540.26 | $22K |
| Jan 9, 2026 | Taub Rebecca | Director | Sell(S) | 400 | $542.72 | $217K |
| Jan 9, 2026 | Taub Rebecca | Director | Option exercise(M) | 18K | $15.80 | $291K |
| Jan 9, 2026 | Taub Rebecca | Director | Sell(S) | 960 | $512.02 | $492K |
| Jan 9, 2026 | Taub Rebecca | Director | Sell(S) | 960 | $513.12 | $493K |
| Jan 9, 2026 | Taub Rebecca | Director | Sell(S) | 937 | $514.63 | $482K |
| Jan 9, 2026 | Taub Rebecca | Director | Sell(S) | 2K | $515.82 | $814K |
| Jan 9, 2026 | Taub Rebecca | Director | Sell(S) | 521 | $516.81 | $269K |
| Jan 9, 2026 | Taub Rebecca | Director | Sell(S) | 2K | $517.84 | $1.1M |
| Jan 9, 2026 | Taub Rebecca | Director | Sell(S) | 970 | $518.67 | $503K |
| Jan 9, 2026 | Taub Rebecca | Director | Sell(S) | 539 | $519.89 | $280K |
| Jan 9, 2026 | Taub Rebecca | Director | Sell(S) | 440 | $521.11 | $229K |
| Jan 9, 2026 | Taub Rebecca | Director | Sell(S) | 588 | $521.95 | $307K |
| Jan 9, 2026 | Taub Rebecca | Director | Sell(S) | 732 | $522.98 | $383K |
| Jan 9, 2026 | Taub Rebecca | Director | Sell(S) | 1K | $524.06 | $700K |
| Jan 9, 2026 | Taub Rebecca | Director | Sell(S) | 1K | $525.12 | $782K |
| Jan 9, 2026 | Taub Rebecca | Director | Sell(S) | 913 | $526.05 | $480K |
| Jan 9, 2026 | Taub Rebecca | Director | Sell(S) | 1K | $526.95 | $598K |
| Jan 9, 2026 | Taub Rebecca | Director | Option exercise(M) | 18K | — | $0 |
| Jan 9, 2026 | Taub Rebecca | Director | Sell(S) | 200 | $551.24 | $110K |
| Jan 9, 2026 | Taub Rebecca | Director | Option exercise(M) | 240 | $15.80 | $4K |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Coverage: Form 4 filings indexed 2021-03-29 → 2026-07-14. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).